Half-Year 2022 Financial and Clinical Trials Update

HY 2022: Core net financial result Roche Higher net financial expenses driven by loss on Equity securities and higher interest expenses CHFM -186 • -220 Net financial expense increased by -370m at CER Interest expenses¹increased by +49% at CER +26 -10 -88 -80 -558 HY 2021 Equity securities Net interest income FX G/L Interest expenses¹ Other HY 2022 CER-Constant Exchange Rates; 1 incl. amortization of debt discount and net gains on interest rate derivatives 59

View entire presentation